Side-by-side · Research reference

GHRP-6vsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED10/36 cited

BPhase 3HUMAN-REVIEWED25/54 cited

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

GHRP-6

Survodutide

Primary target

Ghrelin receptor (GHS-R1a)Bowers 1990

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

—

Origin

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

—

Antibody development

—

02Dosage Protocols

Parameter

GHRP-6

Survodutide

Standard dose

100–200 mcg per injectionBowers 1990

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

1–3× per day

Once weekly

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 + clinical practiceBowers 1990

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

8–12 weeks on / 4 off

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-meal preferred for appetite support

—

Half-life

~15 minMalagón 1999

—

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

GHRP-6

Survodutide

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

GHRP-6

Survodutide

Hunger

Pronounced — defining feature vs ipamorelin

—

Cortisol elevation

Mild

—

Prolactin elevation

Mild

—

Injection site reaction

Mild

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

GHRP-6

Survodutide

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Injection site

SQ — abdomen. Rotate sites.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Pre-meal for appetite support; pre-sleep for GH alignment.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Needle

29–31G, 4–8 mm insulin syringe.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.